


21  
This application is a continuation in part of Serial Number 08/741,066 filed on October 30, 1996 (now issued as Patent No 6,403,599) which claims benefit of 60/006,333 filed November 8, 1995, and also is a continuation in part of application Serial No 09/254,387 filed March 4, 1999 (now issued as Patent No 6,316,631) which is the United States part of International Patent Application PCT/IB95/00437 which was filed on June 6, 1995

## IN THE CLAIMS

Please amend claims 1,2, 3 4, 14 and 15 to read as follows:

1(Amended) A compound of the formula



or a pharmaceutically acceptable salt thereof, wherein

A is  $-\text{CR}_7$  or N;

B is  $-\text{NR}_1\text{R}_2$ ,  $-\text{CR}_1\text{R}_2\text{R}_{11}$ ,  $-\text{C}(=\text{CR}_2\text{R}_{12})\text{R}_b$ ,  $-\text{NHCHR}_1\text{R}_2$ ,  $-\text{OCHR}_1\text{R}_2$ ,  $-\text{SCHR}_1\text{R}_2$ ,  $-\text{CHR}_2\text{OR}_1$ ,  $-\text{CHR}_1\text{OR}_2$ ,  $-\text{CHR}_2\text{SR}_1$ ,  $-\text{C}(\text{S})\text{R}_2$ ,  $-\text{C}(\text{O})\text{R}_2$ ,  $-\text{CHR}_2\text{NR}_1\text{R}_2$ ,  $-\text{CHR}_1\text{NHR}_2$ ,  $-\text{CHR}_1\text{N}(\text{CH}_3)\text{R}_2$ , or  $-\text{NR}_{12}\text{NR}_1\text{R}_2$ ;

Y is CH or N;

22  
 $\text{R}_1$  is  $\text{C}(\text{O})\text{H}$ ,  $\text{C}(\text{O})(\text{C}_1\text{-C}_6 \text{ hydrocarbyl})$ ,  $\text{C}(\text{O})(\text{C}_1\text{-C}_6 \text{ hydrocarbylene})(\text{C}_3\text{-C}_8 \text{ cyclohydrocarbyl})$ ,  $\text{C}(\text{O})(\text{C}_3\text{-C}_8 \text{ cyclohydrocarbylene})(\text{C}_3\text{-C}_8 \text{ cyclohydrocarbyl})$ ,  $\text{C}(\text{O})(\text{C}_1\text{-C}_6 \text{ hydrocarbylene})(\text{C}_4\text{-C}_8 \text{ heterocyclohydrocarbyl})$ ,  $-\text{C}(\text{O})(\text{C}_3\text{-C}_8 \text{ cyclohydrocarbylene})(\text{C}_4\text{-C}_8 \text{ heterocyclohydrocarbyl})$ ,  $\text{C}_1\text{-C}_6 \text{ hydrocarbyl}$ ,  $\text{C}_3\text{-C}_8 \text{ cyclohydrocarbyl}$ ,  $\text{C}_4\text{-C}_8 \text{ heterocyclohydrocarbyl}$ ,  $-(\text{C}_1\text{-C}_6 \text{ hydrocarbylene})(\text{C}_3\text{-C}_8 \text{ cyclohydrocarbyl})$ ,  $\text{C}_3\text{-C}_8 \text{ cyclohydrocarbylene})(\text{C}_3\text{-C}_8 \text{ cyclohydrocarbyl})$ ,  $-(\text{C}_1\text{-C}_6 \text{ hydrocarbylene})(\text{C}_4\text{-C}_8 \text{ heterocyclohydrocarbyl})$ ,  $-(\text{C}_3\text{-C}_8 \text{ cyclohydrocarbylene})(\text{C}_4\text{-C}_8 \text{ heterocyclohydrocarbyl})$ , or  $-\text{O-aryl}$ , or  $-\text{O}-(\text{C}_1\text{-C}_6 \text{ hydrocarbylene})\text{-aryl}$ ; wherein said aryl,  $\text{C}_4\text{-C}_8 \text{ heterocyclohydrocarbyl}$ ,  $\text{C}_1\text{-C}_6 \text{ hydrocarbyl}$ ,  $\text{C}_3\text{-C}_8 \text{ cyclohydrocarbyl}$ ,  $\text{C}_3\text{-C}_8 \text{ cyclohydrocarbylene}$ , and

C<sub>1</sub>-C<sub>6</sub> hydrocarbylene groups may each independently be optionally substituted with from one to six fluoro and may each independently be optionally substituted with one or two substituents R<sub>8</sub> independently selected from the group consisting of C<sub>1</sub>-C<sub>4</sub> hydrocarbyl, -C<sub>3</sub>-C<sub>8</sub> cyclohydrocarbyl, hydroxy, chloro, bromo, iodo, CF<sub>3</sub>, -O-(C<sub>1</sub>-C<sub>6</sub> hydrocarbyl), -O-(C<sub>3</sub>-C<sub>8</sub> cyclohydrocarbyl), -O-CO-(C<sub>1</sub>-C<sub>4</sub> hydrocarbyl), -O-CO-NH(C<sub>1</sub>-C<sub>4</sub> hydrocarbyl), -O-CO-N(R<sub>24</sub>)(R<sub>25</sub>), -N(R<sub>24</sub>)(R<sub>25</sub>), -S(C<sub>1</sub>-C<sub>4</sub> hydrocarbyl), -S(C<sub>3</sub>-C<sub>8</sub> cyclohydrocarbyl) -N(C<sub>1</sub>-C<sub>4</sub> hydrocarbyl)CO(C<sub>1</sub>-C<sub>4</sub> hydrocarbyl), -NHCO(C<sub>1</sub>-C<sub>4</sub> hydrocarbyl), -COO(C<sub>1</sub>-C<sub>4</sub> hydrocarbyl), -CONH(C<sub>1</sub>-C<sub>4</sub> hydrocarbyl), -CONC<sub>1</sub>-C<sub>4</sub> hydrocarbyl)(C<sub>1</sub>-C<sub>2</sub> hydrocarbyl), CN, NO<sub>2</sub>, -OSO<sub>2</sub>(C<sub>1</sub>-C<sub>4</sub> hydrocarbyl), S<sup>+</sup>(C<sub>1</sub>-C<sub>6</sub> hydrocarbyl)(C<sub>1</sub>-C<sub>2</sub> hydrocarbyl), -SO(C<sub>1</sub>-C<sub>4</sub> hydrocarbyl) and -SO<sub>2</sub>(C<sub>1</sub>-C<sub>4</sub> hydrocarbyl); and wherein the C<sub>1</sub>-C<sub>6</sub> hydrocarbyl, C<sub>1</sub>-C<sub>6</sub> hydrocarbylene, C<sub>5</sub>-C<sub>8</sub> cyclohydrocarbyl, C<sub>5</sub>-C<sub>8</sub> cyclohydrocarbylene, and C<sub>5</sub>-C<sub>8</sub> heterocyclohydrocarbyl moieties of R<sub>1</sub> may optionally independently contain from one to three double or triple bonds; and wherein the C<sub>1</sub>-C<sub>4</sub> hydrocarbyl moieties and C<sub>1</sub>-C<sub>6</sub> hydrocarbyl moieties of R<sub>8</sub> can optionally independently be substituted with hydroxy, amino, C<sub>1</sub>-C<sub>4</sub> alkyl, aryl, -CH<sub>2</sub>-aryl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl, or -O-(C<sub>1</sub>-C<sub>4</sub> alkyl), and can optionally independently be substituted with from one to six fluoro, and can optionally contain one or two double or triple bonds; and wherein each heterocyclohydrocarbyl group of R<sub>1</sub> contains from one to three heteromoieties selected from oxygen, S(O)<sub>m</sub>, nitrogen, and NR<sub>12</sub>;

R<sub>2</sub> is hydrogen, C<sub>1</sub>-C<sub>12</sub> hydrocarbyl, C<sub>3</sub>-C<sub>8</sub> cyclohydrocarbyl, C<sub>4</sub>-C<sub>8</sub> heterocyclohydrocarbyl, -(C<sub>1</sub>-C<sub>6</sub> hydrocarbylene)(C<sub>3</sub>-C<sub>8</sub> cyclohydrocarbyl), -(C<sub>3</sub>-C<sub>8</sub> cyclohydrocarbylene)(C<sub>3</sub>-C<sub>8</sub> cyclohydrocarbyl), -(C<sub>1</sub>-C<sub>6</sub> hydrocarbylene)(C<sub>4</sub>-C<sub>8</sub> heterocyclohydrocarbyl), -(C<sub>3</sub>-C<sub>8</sub> cyclohydrocarbylene)(C<sub>4</sub>-C<sub>8</sub> heterocyclohydrocarbyl), aryl, -(C<sub>1</sub>-C<sub>6</sub> hydrocarbylene)aryl, or -(C<sub>3</sub>-C<sub>8</sub> cyclohydrocarbylene)(aryl); wherein each of the foregoing R<sub>2</sub> groups may optionally be substituted with from one to three substituents independently selected from chloro, fluoro, and C<sub>1</sub>-C<sub>6</sub> alkyl, wherein one of said one to three substituents can further be selected from bromo, iodo, C<sub>1</sub>-C<sub>6</sub> alkoxy, -OH, -O-CO-(C<sub>1</sub>-C<sub>6</sub> alkyl), -O-CO-N(C<sub>1</sub>-C<sub>4</sub> alkyl)(C<sub>1</sub>-C<sub>2</sub> alkyl), -S(C<sub>1</sub>-C<sub>6</sub> alkyl), -S(O)(C<sub>1</sub>-C<sub>6</sub> alkyl), -S(O)<sub>2</sub>(C<sub>1</sub>-C<sub>6</sub> alkyl), S<sup>+</sup>(C<sub>1</sub>-C<sub>6</sub> alkyl)(C<sub>1</sub>-C<sub>2</sub> alkyl)I', CN, and NO<sub>2</sub>; and wherein the C<sub>1</sub>-C<sub>12</sub> hydrocarbyl, -(C<sub>1</sub>-C<sub>6</sub> hydrocarbylene), and cyclohydrocarbyl groups of 5 - 8 carbon atoms, cyclohydrocarbylene groups of 5 to 8 carbon atoms and heterocyclohydrocarbyl groups of 5 to 8 atoms of R<sub>2</sub> may optionally independently contain from one to three double or triple bonds; and wherein each heterocyclohydrocarbyl group of R<sub>2</sub> contains from one to three heteromoieties selected from oxygen, S(O)<sub>m</sub>, nitrogen, and NR<sub>12</sub>;

or when  $R_1$  and  $R_2$  are as in  $-NHCHR_1R_2$ ,  $-OCHR_1R_2$ ,  $-SCHR_1R_2$ ,  $-CHR_1R_2$  or  $-NR_1R_2$ ,  $R_1$  and  $R_2$  of B may form a saturated 5- to 8-membered ring which may optionally contain one or two double bonds and in which one or two of the ring carbons may optionally be replaced by an oxygen,  $S(O)_m$ , nitrogen or  $NR_{12}$ ; and which carbocyclic ring can optionally be substituted with from 1 to 3 substituents selected from the group consisting of hydroxy,  $C_1$ - $C_4$  alkyl, fluoro, chloro, bromo, iodo,  $CF_3$ ,  $-O-(C_1-C_4 \text{ alkyl})$ ,  $-O-CO-(C_1-C_4 \text{ alkyl})$ ,  $-O-CO-NH(C_1-C_4 \text{ alkyl})$ ,  $-O-CO-N(C_1-C_4 \text{ alkyl})(C_1-C_2 \text{ alkyl})$ ,  $-NH(C_1-C_4 \text{ alkyl})$ ,  $-N(C_1-C_2 \text{ alkyl})(C_1-C_4 \text{ alkyl})$ ,  $-S(C_1-C_4 \text{ alkyl})$ ,  $-N(C_1-C_4 \text{ alkyl})CO(C_1-C_4 \text{ alkyl})$ ,  $-NHCO(C_1-C_4 \text{ alkyl})$ ,  $-COO(C_1-C_4 \text{ alkyl})$ ,  $-CONH(C_1-C_4 \text{ alkyl})$ ,  $-CON(C_1-C_4 \text{ alkyl})(C_1-C_2 \text{ alkyl})$ ,  $CN$ ,  $NO_2$ ,  $-OSO_2(C_1-C_4 \text{ alkyl})$ ,  $-SO(C_1-C_4 \text{ alkyl})$ , and  $-SO(C_1-C_4 \text{ alkyl})$ , wherein one of said one to three substituents can further be selected from phenyl;

$R_3$  is methyl, ethyl, fluoro, chloro, bromo, iodo, cyano, methoxy,  $OCF_3$ ,  $NH_2$ ,  $NH(C_1-C_2 \text{ alkyl})$ ,  $N(CH_3)_2$ ,  $-NHCOCF_3$ ,  $-NHCH_2CF_3$ ,  $S(O)_m(C_1-C_4 \text{ alkyl})$ ,  $CONH_2$ ,  $-CONHCH_3$ ,  $CON(CH_3)_2$ ,  $-CF_3$ , or  $CH_2OCH_3$ ;

$R_4$  is hydrogen,  $C_1$ - $C_4$  hydrocarbyl,  $C_3$ - $C_5$  cycloalkyl,  $-(C_1-C_4 \text{ hydrocarbylene})(C_3-C_5 \text{ cycloalkyl})$ ,  $-(C_3-C_5 \text{ cycloalkylene})(C_3-C_6 \text{ cycloalkyl})$ , cyano, fluoro, chloro, bromo, iodo,  $-OR_{24}$ ,  $C_1$ - $C_6$  alkoxy,  $-O$ -cycloalkyl,  $-O-(C_1-C_4 \text{ hydrocarbylene})(C_3-C_5 \text{ cycloalkyl})$ ,  $-O-(C_3-C_5 \text{ cycloalkylene})(C_3-C_5 \text{ cycloalkyl})$ ,  $-CH_2SC(S)O(C_1-C_4 \text{ alkyl})$ ,  $CH_2OCF_3$ ,  $CF_3$ , amino, nitro,  $-NR_{24}R_{25}$ ,  $-(C_1-C_4 \text{ hydrocarbylene})-OR_{24}$ ,  $-(C_1-C_4 \text{ hydrocarbylene})Cl$ ,  $-(C_1-C_4 \text{ hydrocarbylene})NR_{24}R_{25}$ ,  $-NHCOR_{24}$ ,  $-NHCONR_{24}R_{25}$ ,  $-CH=NOR_{24}$ ,  $-NHNOR_{24}R_{25}$ ,  $-S(O)_mR_{24}$ ,  $-C(O)R_{24}$ ,  $-OC(O)R_{24}$ ,  $-C(O)CN$ ,  $-C(O)NR_{24}R_{25}$ ,  $-C(O)NHNOR_{24}R_{25}$ , and  $-COOR_{24}$ , wherein the hydrocarbyl and hydrocarbylene groups of  $R_4$  may optionally independently contain one or two double or triple bonds and may optionally independently be substituted with one or two substituents  $R_{10}$  independently selected from hydroxy, amino,  $-NHCOCH_3$ ,  $-NHCOCH_2Cl$ ,  $-NH(C_1-C_2 \text{ alkyl})$ ,  $-N(C_1-C_2 \text{ alkyl})(C_1-C_2 \text{ alkyl})$ ,  $-COO(C_1-C_4 \text{ alkyl})$ ,  $-COOH$ ,  $-CO(C_1-C_4 \text{ alkyl})$ ,  $C_1$ - $C_6$  alkoxy,  $C_1$ - $C_3$  thioalkyl, cyano and nitro, and with one to four substituents independently selected from fluoro and chloro;

$R_5$  is aryl or heteroaryl and is substituted with from one to four substituents  $R_{27}$  independently selected from halo,  $C_1$ - $C_{10}$  hydrocarbyl,  $-(C_1-C_4 \text{ hydrocarbylene})(C_3-C_8 \text{ cycloalkyl})$ ,  $-(C_1-C_4 \text{ hydrocarbylene})(C_4-C_8 \text{ heterocycloalkyl})$ ,  $-(C_3-C_8 \text{ cycloalkyl})$ ,  $-(C_4-C_8 \text{ heterocycloalkyl})$ ,  $-(C_3-C_8 \text{ cycloalkylene})(C_3-C_8 \text{ cycloalkyl})$ ,  $-(C_3-C_8 \text{ cycloalkylene})(C_4-C_8 \text{ heterocycloalkyl})$ ,  $C_1$ - $C_4$  haloalkyl,  $C_1$ - $C_4$  haloalkoxy, nitro, cyano,  $-NR_{24}R_{25}$ ,  $-NR_{24}COR_{25}$ ,  $-NR_{24}CO_2R_{26}$ ,  $-COR_{24}$ ,  $-OR_{25}$ ,  $-CONR_{24}R_{25}$ ,  $-CON(OR_{22})R_{23}$ ,  $-CO_2R_{26}$ ,  $-C=N(OR_{22})R_{23}$ , and  $-S(O)_mR_{23}$ ; wherein said  $C_1$ - $C_{10}$  alkyl,  $C_3$ - $C_8$  cycloalkyl,  $(C_1-C_4 \text{ hydrocarbylene})$ ,  $(C_3-C_8 \text{ cycloalkyl})$ ,  $(C_3-C_8 \text{ cycloalkylene})$ , and  $(C_4-C_8$

heterocycloalkyl) groups can be optionally substituted with from one to three substituents independently selected from  $C_1$ - $C_4$  alkyl,  $C_3$ - $C_8$  cycloalkyl,  $(C_1$ - $C_4$  hydrocarbylene)( $C_3$ - $C_8$  cycloalkyl),  $-(C_3$ - $C_8$  cycloalkylene)( $C_3$ - $C_8$  cycloalkyl),  $C_1$ - $C_4$  haloalkyl, hydroxy,  $C_1$ - $C_6$  alkoxy, nitro halo, cyano,  $-NR_{24}R_{25}$ ,  $-NR_{24}COR_{25}$ ,  $NR_{24}CO_2R_{26}$ ,  $-COR_{24}$ ,  $-OR_{25}$ ,  $-CONR_{24}R_{25}$ ,  $CO_2R_{26}$ ,  $-CO(NOR_{22})R_{25}$ , and  $-S(O)_mR_{23}$ ; and wherein two adjacent substituents of the  $R_5$  group can optionally form a 5-7 membered ring, saturated or unsaturated, fused to  $R_5$ , which ring optionally can contain one, two, or three heterologous members independently selected from O,  $S(O)_m$ , and N, but not any  $-S-S-$ ,  $-O-O-$ ,  $-S-O-$ , or  $-N-S-$  bonds, and which ring is optionally substituted with  $C_1$ - $C_4$  alkyl,  $C_3$ - $C_8$  cycloalkyl,  $-(C_1$ - $C_4$  alkylene)( $C_3$ - $C_8$  cycloalkyl),  $-(C_3$ - $C_8$  cycloalkylene)( $C_3$ - $C_8$  cycloalkyl),  $C_1$ - $C_4$  haloalkyl, nitro, halo, cyano  $-NR_{24}R_{25}$ ,  $NR_{24}COR_{25}$ ,  $NR_{24}CO_2R_{26}$ ,  $-COR_{24}$ ,  $-OR_{25}$ ,  $-CONR_{24}R_{25}$ ,  $CO_2R_{26}$ ,  $-CO(NOR_{26})R_{25}$ , or  $-S(O)_mR_{23}$ ; wherein one of said one to four optional substituents  $R_{27}$ , can further be selected from  $-SO_2NH(C_1$ - $C_4$  alkyl),  $-SO_2NH(C_1$ - $C_4$  alkylene)( $C_3$ - $C_8$  cycloalkyl),  $SO_2NH(C_3$ - $C_8$  cycloalkyl),  $-SO_2NH(C_3$ - $C_8$  cycloalkylene)( $C_3$ - $C_8$  cycloalkyl),  $-SO_2N(C_1$ - $C_4$  alkyl)( $C_1$ - $C_2$  alkyl),  $-SO_2NH_2$ ,  $-NHSO_2(C_1$ - $C_4$  alkyl),  $-NHSO_2(C_3$ - $C_8$  cycloalkyl),  $-NHSO_2(C_1$ - $C_4$  alkylene)( $C_3$ - $C_8$  cycloalkyl), and  $-NHSO_2(C_3$ - $C_8$  cycloalkylene)( $C_3$ - $C_8$  cycloalkyl); and wherein the hydrocarbyl, and hydrocarbylene groups of  $R_5$  may independently optionally contain one double or triple bond;  $R_6$  is hydrogen,  $C_1$ - $C_6$  alkyl,  $C_3$ - $C_8$  cycloalkyl,  $-(C_1$ - $C_6$  alkylene)( $C_3$ - $C_8$  cycloalkyl), or  $-(C_3$ - $C_8$  cycloalkylene)( $C_3$ - $C_8$  cycloalkyl), wherein said alkyl and cycloalkyl may optionally be substituted with one hydroxy, methoxy, ethoxy or fluoro group;

or  $R_6$  and  $R_4$  can together form an oxo ( $=O$ ) group, or can be connected to form a 3-8 membered carbocyclic ring, optionally containing one to three double bonds, and optionally containing one, two, or three heterologous ring members selected from O,  $SO_m$ , N, and  $NR_{12}$ , but not containing any  $-O-O-$ ,  $-S-O-$ ,  $-S-S-$ , or  $-N-S-$  bonds, and further optionally substituted with  $C_1$ - $C_4$  hydrocarbyl or  $C_3$ - $C_6$  cycloalkyl, wherein said  $C_1$ - $C_4$  hydrocarbyl substituent may optionally contain one double or triple bond;

$R_7$  is hydrogen, methyl, fluoro, chloro, bromo, iodo, cyano, hydroxy,  $-O(C_1$ - $C_2$  alkyl),  $-O$ (cyclopropyl),  $-COO(C_1$ - $C_2$  alkyl),  $-COO(C_3$ - $C_8$  cycloalkyl),  $-OCF_3$ ,  $CF_3$ ,  $-CH_2OH$ , or  $CH_2OCH_3$ ;

$R_{11}$  is hydrogen, hydroxy, fluoro, ethoxy, or methoxy;

$R_{12}$  is hydrogen or  $C_1$ - $C_4$  alkyl;

$R_{16}$  and  $R_{17}$  are each, independently, hydrogen, hydroxy, methyl, ethyl, methoxy, or ethoxy, except that  $R_{16}$  and  $R_{17}$  are not both methoxy or ethoxy;

or  $R_{16}$  and  $R_{17}$  together form an oxo ( $=O$ ) group;

or  $R_{16}$  and  $R_{17}$  are connected to form a 3-8 membered carbocyclic ring, optionally containing one to three double bonds, and optionally containing from one to three heterologous ring members selected from O,  $SO_m$ , N, and  $NR_{12}$ , but not containing any  $-O-O-$ ,  $-S-O-$ ,  $-S-S-$ , or  $-N-S-$

bonds, and further optionally substituted with C<sub>1</sub>-C<sub>4</sub> hydrocarbonyl or C<sub>3</sub>-C<sub>6</sub> cycloalkyl, wherein said C<sub>1</sub>-C<sub>4</sub> hydrocarbonyl substituent may optionally contain one double or triple bond;

R<sub>22</sub> is independently at each occurrence selected from hydrogen, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> haloalkyl, C<sub>3</sub>-C<sub>6</sub> alkenyl, C<sub>3</sub>-C<sub>6</sub> alkynyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl, (C<sub>3</sub>-C<sub>8</sub> cycloalkylene)(C<sub>3</sub>-C<sub>8</sub> cycloalkyl), and (C<sub>1</sub>-C<sub>4</sub> alkylene)(C<sub>3</sub>-C<sub>8</sub> cycloalkyl);

R<sub>22</sub> is independently at each occurrence selected from hydrogen, C<sub>1</sub>-C<sub>14</sub> alkyl, C<sub>1</sub>-C<sub>14</sub> haloalkyl, C<sub>3</sub>-C<sub>6</sub> alkenyl, C<sub>3</sub>-C<sub>6</sub> alkynyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl, (C<sub>3</sub>-C<sub>8</sub> cycloalkylene)(C<sub>3</sub>-C<sub>8</sub> cycloalkyl), and (C<sub>1</sub>-C<sub>4</sub> alkylene)(C<sub>3</sub>-C<sub>8</sub> cycloalkyl);

R<sub>23</sub> is independently at each occurrence selected from C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> haloalkyl, C<sub>2</sub>-C<sub>8</sub> alkoxyalkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl, -(C<sub>1</sub>-C<sub>4</sub> alkylene)(C<sub>3</sub>-C<sub>8</sub> cycloalkyl), -(C<sub>3</sub>-C<sub>8</sub> cycloalkylene)(C<sub>3</sub>-C<sub>8</sub> cycloalkyl), aryl, -(C<sub>1</sub>-C<sub>4</sub> alkylene)aryl, piperidine, pyrrolidine, piperazine, N-methylpiperazine, morpholine, and thiomorpholine;

R<sub>24</sub> and R<sub>25</sub> are independently at each occurrence selected from hydrogen, -C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> haloalkyl, -(C<sub>1</sub>-C<sub>4</sub> alkylene)OH, -(C<sub>1</sub>-C<sub>4</sub> alkylene)-O-(C<sub>1</sub>-C<sub>4</sub> alkyl), -(C<sub>1</sub>-C<sub>4</sub> alkylene)-O-(C<sub>3</sub>-C<sub>5</sub> cycloalkyl), C<sub>3</sub>-C<sub>8</sub> cycloalkyl, -(C<sub>1</sub>-C<sub>4</sub> alkylene)(C<sub>3</sub>-C<sub>8</sub> cycloalkyl), -(C<sub>3</sub>-C<sub>8</sub> cycloalkylene)(C<sub>3</sub>-C<sub>8</sub> cycloalkyl), -C<sub>4</sub>-C<sub>8</sub> heterocyclohydrocarbonyl, -(C<sub>1</sub>-C<sub>4</sub> alkylene)(C<sub>4</sub>-C<sub>8</sub> heterocyclohydrocarbonyl), -(C<sub>3</sub>-C<sub>8</sub> cycloalkylene)(C<sub>4</sub>-C<sub>8</sub> heterocyclohydrocarbonyl), aryl, and -(C<sub>1</sub>-C<sub>4</sub> alkylene)(aryl), wherein the -C<sub>4</sub>-C<sub>8</sub> heterocyclohydrocarbonyl groups can each independently optionally be substituted with aryl, CH<sub>2</sub>-aryl, or C<sub>1</sub>-C<sub>4</sub> alkyl, and can optionally contain one or two double or triple bonds; or, when R<sub>24</sub> and R<sub>25</sub> are as NR<sub>24</sub>R<sub>25</sub>, -C(O)NR<sub>24</sub>R<sub>25</sub>, -(C<sub>1</sub>-C<sub>4</sub> alkylene)NR<sub>24</sub>R<sub>25</sub>, or -NHCONR<sub>24</sub>R<sub>25</sub>, then NR<sub>24</sub>R<sub>25</sub>


may further optionally form a 4 to 8 membered heterocyclic ring optionally containing one or two further hetero members independently selected from S(O)<sub>m</sub>, oxygen, nitrogen, and NR<sub>12</sub>, and optionally containing from one to three double bonds;

R<sub>26</sub> is independently at each occurrence selected from C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> haloalkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl, -(C<sub>1</sub>-C<sub>4</sub> alkylene)(C<sub>3</sub>-C<sub>8</sub> cycloalkyl), -(C<sub>3</sub>-C<sub>8</sub> cycloalkylene)(C<sub>3</sub>-C<sub>8</sub> cycloalkyl), aryl, and -(C<sub>1</sub>-C<sub>4</sub> alkylene)(aryl); and

wherein each m is independently zero, one, or two,

with the proviso that heterocyclohydrocarbonylene groups of the compound of formula II, do not comprise any -S-S-, -S-O-, -N-S-, or -O-O- bonds, and do not comprise more than two oxygen or S(O)<sub>m</sub> heterologous members.

2.(Amended) A compound according to claim 1 of the formula



or a pharmaceutically acceptable salt thereof, wherein

A is  $-\text{CR}_7$  or N;

B is  $-\text{NR}_1\text{R}_2$ ,  $-\text{CR}_1\text{R}_2\text{R}_{11}$ ,  $-\text{C}(=\text{CR}_2\text{R}_{12})\text{R}_1$ ,  $-\text{NHCHR}_1\text{R}_2$ ,  $-\text{OCHR}_1\text{R}_2$ ,  $-\text{SCHR}_1\text{R}_2$ ,  $-\text{CHR}_2\text{OR}_{12}$ ,  $-\text{CHR}_2\text{SR}_{12}$ ,  $-\text{C}(\text{S})\text{R}_2$  or  $-\text{C}(\text{O})\text{R}_2$ ;

Y is  $-\text{CH}$  or N;

$\text{R}_1$  is  $\text{C}_1\text{-C}_6$  hydrocarbyl which may optionally be substituted with one or two substituents  $\text{R}_8$  independently selected from the group consisting of hydroxy, fluoro, chloro, bromo, iodo,  $\text{CF}_3$ ,  $\text{C}_1\text{-C}_4$  alkoxy,  $-\text{O}-\text{CO}-(\text{C}_1\text{-C}_4 \text{ hydrocarbyl})$ ,  $-\text{O}-\text{CO}-\text{NH}(\text{C}_1\text{-C}_4 \text{ hydrocarbyl})$ ,  $-\text{O}-\text{CO}-\text{N}(\text{C}_1\text{-C}_4 \text{ hydrocarbyl})(\text{C}_1\text{-C}_2 \text{ hydrocarbyl})$ ,  $-\text{NH}(\text{C}_1\text{-C}_4 \text{ hydrocarbyl})$ ,  $-\text{N}(\text{C}_1\text{-C}_2 \text{ alkyl})(\text{C}_1\text{-C}_4 \text{ hydrocarbyl})$ ,  $-\text{S}(\text{C}_1\text{-C}_4 \text{ alkyl})$ ,  $-\text{N}(\text{C}_1\text{-C}_4) \text{CO}(\text{C}_1\text{-C}_4 \text{ hydrocarbyl})$ ,  $-\text{NHCO}(\text{C}_1\text{-C}_4 \text{ hydrocarbyl})$ ,  $-\text{COO}(\text{C}_1\text{-C}_4 \text{ hydrocarbyl})\text{hydrocarbyl}$ ,  $-\text{CONH}(\text{C}_1\text{-C}_4 \text{ hydrocarbyl})$ ,  $-\text{CON}(\text{C}_1\text{-C}_4 \text{ hydrocarbyl})(\text{C}_1\text{-C}_2 \text{ alkyl})$ , CN,  $\text{NO}_2$ ,  $-\text{SO}(\text{C}_1\text{-C}_4 \text{ hydrocarbyl})$  and  $-\text{SO}_2(\text{C}_1\text{-C}_4 \text{ hydrocarbyl})$ , and wherein said  $\text{C}_1\text{-C}_6$  hydrocarbyl and the  $(\text{C}_1\text{-C}_4)\text{hydrocarbyl}$  moieties in the foregoing  $\text{R}_1$  groups may optionally contain one carbon-carbon double or triple bond;

$\text{R}_2$  is  $\text{C}_1\text{-C}_{12}$  hydrocarbyl, aryl or  $-(\text{C}_1\text{-C}_4 \text{ hydrocarbylene})\text{aryl}$  wherein said aryl is phenyl, naphthyl, thienyl, benzothienyl, pyridyl, quinolyl, pyrazinyl, pyrimidyl, imidazolyl, furanyl, benzofuranyl, benzothiazolyl, isothiazolyl, benzisothiazolyl, benzisoxazolyl, benzimidazolyl, indolyl, or benzoxazolyl; 3- to 8-membered cycloalkyl or  $-(\text{C}_1\text{-C}_6 \text{ alkylene})\text{cycloalkyl}$ , wherein one or two of the ring carbons of said cycloalkyl having at least 4 ring members and the cycloalkyl moiety of said  $-(\text{C}_1\text{-C}_6 \text{ alkylene})\text{cycloalkyl}$  having at least 4 ring members may optionally be replaced by an oxygen or sulfur atom or by  $\text{N}-\text{R}_9$ , wherein  $\text{R}_9$  is hydrogen or  $\text{C}_1\text{-C}_4$  alkyl; and wherein each of the foregoing  $\text{R}_2$  groups may optionally be substituted with from one to three substituents independently selected from chloro, fluoro and  $\text{C}_1\text{-C}_4$  alkyl, or with one substituent selected from bromo, iodo,  $\text{C}_1\text{-C}_6$  alkoxy,

17  
-O-CO-(C<sub>1</sub>-C<sub>6</sub> alkyl), -O-CO-N(C<sub>1</sub>-C<sub>4</sub> alkyl)(C<sub>1</sub>-C<sub>2</sub> alkyl), -S(C<sub>1</sub>-C<sub>6</sub> alkyl), CN, NO<sub>2</sub>, -SO(C<sub>1</sub>-C<sub>4</sub> alkyl), and -SO<sub>2</sub>(C<sub>1</sub>-C<sub>4</sub> alkyl), and wherein said C<sub>1</sub>-C<sub>12</sub> hydrocarbyl and the C<sub>1</sub>-C<sub>4</sub> hydrocarbylene moiety of said -(C<sub>1</sub>-C<sub>4</sub> hydrocarbylene)aryl may optionally contain one carbon-carbon double or triple bond;

or -NR<sub>1</sub>R<sub>2</sub> or -CR<sub>1</sub>R<sub>2</sub>R<sub>11</sub> may form a saturated 5- to 8-membered carbocyclic ring which may optionally contain one or two carbon-carbon double bonds and in which one or two of the ring carbons may optionally be replaced by an oxygen or sulfur atom;

R<sub>3</sub> is methyl, ethyl, fluoro, chloro, bromo, iodo, cyano, methoxy, OCF<sub>3</sub>, methylthio, methylsulfonyl, CH<sub>2</sub>OH, or CH<sub>2</sub>OCH<sub>3</sub>;

R<sub>4</sub> is hydrogen, C<sub>1</sub>-C<sub>4</sub> hydrocarbyl, fluoro, chloro, bromo, iodo, C<sub>1</sub>-C<sub>4</sub> alkoxy, trifluoromethoxy, -CH<sub>2</sub>OCH<sub>3</sub>, -CH<sub>2</sub>OCH<sub>2</sub>CH<sub>3</sub>, -CH<sub>2</sub>CH<sub>2</sub>OCH<sub>3</sub>, -CH<sub>2</sub>OF<sub>3</sub>, CF<sub>3</sub>, amino, nitro, -NH(C<sub>1</sub>-C<sub>4</sub> alkyl), -N(CH<sub>3</sub>)<sub>2</sub>, -NHCOCH<sub>3</sub>, -NHCONHCH<sub>3</sub>, -SO<sub>n</sub>(C<sub>1</sub>-C<sub>4</sub> hydrocarbyl) wherein n is 0, 1 or 2, cyano, hydroxy, -CO(C<sub>1</sub>-C<sub>4</sub> hydrocarbyl), -CHO, cyano or -COO(C<sub>1</sub>-C<sub>4</sub> alkyl) wherein said C<sub>1</sub>-C<sub>4</sub> hydrocarbyl may optionally contain one double or triple bond and may optionally be substituted with one substituent selected from hydroxy, amino, -NHCOCH<sub>3</sub>, -NH(C<sub>1</sub>-C<sub>2</sub> alkyl), -N(C<sub>1</sub>-C<sub>2</sub> alkyl)<sub>2</sub>, -COO(C<sub>1</sub>-C<sub>4</sub> alkyl), -CO(C<sub>1</sub>-C<sub>4</sub> alkyl), C<sub>1</sub>-C<sub>3</sub> alkoxy, C<sub>1</sub>-C<sub>3</sub> thioalkyl, fluoro, chloro, cyano and nitro;

R<sub>5</sub> is phenyl, naphthyl, thienyl, benzothienyl, pyridyl, quinolyl, pyrazinyl, pyrimidyl, furanyl, benzofuranyl, benzothiazolyl, or indolyl, wherein each of the above groups R<sub>5</sub> is substituted with from one to three substituents independently selected from fluoro, chloro, C<sub>1</sub>-C<sub>6</sub> alkyl, and C<sub>1</sub>-C<sub>6</sub> alkoxy, or with one substituent selected from hydroxy, iodo, bromo, formyl, cyano, nitro, trifluoromethyl, amino, -(C<sub>1</sub>-C<sub>6</sub> alkyl)O(C<sub>1</sub>-C<sub>6</sub>)alkyl, -NHCH<sub>3</sub>, -N(CH<sub>3</sub>)<sub>2</sub>, -COOH, -COO(C<sub>1</sub>-C<sub>4</sub> alkyl), -CO(C<sub>1</sub>-C<sub>4</sub> alkyl), -SO<sub>2</sub>NH(C<sub>1</sub>-C<sub>4</sub> alkyl), -SO<sub>2</sub>N(C<sub>1</sub>-C<sub>4</sub> alkyl)(C<sub>1</sub>-C<sub>2</sub> alkyl), -SO<sub>2</sub>NH<sub>2</sub>, -NHSO<sub>2</sub>(C<sub>1</sub>-C<sub>4</sub> alkyl), -S(C<sub>1</sub>-C<sub>6</sub> alkyl) and -SO<sub>2</sub>(C<sub>1</sub>-C<sub>6</sub> alkyl), and wherein the C<sub>1</sub>-C<sub>4</sub> alkyl and C<sub>1</sub>-C<sub>6</sub> alkyl moieties of the foregoing R<sub>5</sub> groups may optionally be substituted with one or two fluoro groups or with one substituent selected from hydroxy, amino, methylamino, dimethylamino and acetyl;

R<sub>6</sub> is hydrogen or C<sub>1</sub>-C<sub>6</sub> alkyl, wherein C<sub>1</sub>-C<sub>6</sub> alkyl may optionally be substituted with one hydroxy, methoxy, ethoxy or fluoro group;

R<sub>7</sub> is hydrogen, methyl, fluoro, chloro, bromo, iodo, cyano, hydroxy, -O(C<sub>1</sub>-C<sub>4</sub> alkyl), -C(O)(C<sub>1</sub>-C<sub>4</sub> alkyl), -C(O)O(C<sub>1</sub>-C<sub>4</sub> alkyl), -OCF<sub>3</sub>, CF<sub>3</sub>, -CH<sub>2</sub>OH, -CH<sub>2</sub>OCH<sub>3</sub> or -CH<sub>2</sub>OCH<sub>2</sub>CH<sub>3</sub>;

R<sub>11</sub> is hydrogen, hydroxy, fluoro, or methoxy;

R<sub>12</sub> is hydrogen or C<sub>1</sub>-C<sub>4</sub> alkyl; and

22  
R<sub>16</sub> and R<sub>17</sub> are each independently, hydrogen, hydroxy, ethyl, methyl, methoxy, or ethoxy, except that R<sub>16</sub> and R<sub>17</sub> are not both methoxy or ethoxy;

or R<sub>16</sub> and R<sub>17</sub> together form an oxo (=O) group;

or a pharmaceutically acceptable salt of such compound.

3. (Amended) A compound according to claim 2 wherein B is  $-NR_1R_2$ ,  $-NHCHR_1R_2$ ,  $-SCHR_1R_2$  or  $-OCHR_1R_2$ ;  $R_1$  is  $C_1-C_6$  hydrocarbyl, which may optionally be substituted with one hydroxy, fluoro,  $CF_3$ , or  $C_1-C_2$  alkoxy group and may optionally contain one double or triple bond; and  $R_2$  is benzyl or  $C_1-C_6$  hydrocarbyl which may optionally contain one carbon-carbon double or triple bond, wherein said  $C_1-C_6$  alkyl or the phenyl moiety of said benzyl may optionally be substituted with fluoro,  $CF_3$ ,  $C_1-C_2$  alkyl, or  $C_1-C_2$  alkoxy.

4. (Amended) A compound according to claim 2 wherein  $R_1$  is  $C_1-C_6$  hydrocarbyl which may be substituted by fluoro,  $CF_3$ , hydroxy,  $C_1-C_2$  alkyl or  $C_1-C_2$  alkoxy and which may optionally contain one carbon-carbon double or triple bond.

14. (Amended) A pharmaceutical composition for the treatment of (a) a disorder or condition the treatment of which can be effected or facilitated by antagonizing CRF or (b) a disorder or condition selected from inflammatory disorders, pain, asthma, psoriasis and allergies; generalized anxiety disorder; panic; phobias; obsessive-compulsive disorder; post-traumatic stress disorder; sleep disorders induced by stress; pain perception such as fibromyalgia; mood disorders, mood disorders associated with premenstrual syndrome, and postpartum depression; dysthemia; bipolar disorders; cyclothymia; chronic fatigue syndrome; stress-induced headache; cancer; irritable bowel syndrome, Crohn's disease; spastic colon; post operative ileus; ulcer; diarrhea; stress-induced fever; human immunodeficiency virus infections; neurodegenerative diseases such as gastrointestinal diseases; eating disorder; hemorrhagic stress; chemical dependencies or addictions; drug or alcohol withdrawal symptoms; stress-induced psychotic episodes; euthyroid sick syndrome; syndrome of inappropriate antidiuretic hormone; obesity; infertility; head trauma; spinal cord trauma; ischemic neuronal damage, including cerebral ischemia; epilepsy; stroke; immune dysfunctions; muscular spasms; urinary incontinence; senile dementia of the Alzheimer's type; multi infarct dementia; amyotrophic lateral sclerosis; hypertension; tachycardia; congestive heart failure; osteoporosis; premature birth; hypoglycemia, and Syndrome X in a mammal or bird, comprising an amount of a compound according to claim 1 that is effective in the treatment of such disorder or condition, and a pharmaceutically acceptable carrier.

15. A pharmaceutical composition according to claim 14 for the treatment of a disorder selected from inflammatory disorders; pain, asthma, psoriasis and allergies; generalized anxiety disorder; panic; phobias; obsessive compulsive disorder; post-traumatic stress disorder; sleep disorders induced by stress; pain perception; mood disorders such as depression, and postpartum depression; dysthemia; bipolar disorders; cyclothymia; fatigue syndrome; stress induced headache; cancer; irritable bowel syndrome, Crohn's disease; spastic colon; human immunodeficiency virus (HIV) infections;



neurodegenerative diseases; gastrointestinal diseases; eating disorders; chemical dependencies and addictions; obesity; infertility; head traumas; spinal cord trauma; ischemic neuronal damage; excitotoxic neuronal damage; epilepsy; stroke; immune dysfunctions; muscular spasms; urinary incontinence; senile dementia of the Alzheimer's type; multi infarct dementia; amyotrophic lateral sclerosis; and hypoglycemia in a mammal, including a human.

Please cancel claims 16-28 without prejudice to the applicants right to file one or more divisional or continuation applications to the subject matter of these claims.

Please add new claims 29 - 40 as follows

- Sub B3*
29. A compound as claimed in claim 1 wherein R24 and R25 are selected from  $\text{CF}_3$ ,  $\text{-CHF}_2$ ,  $\text{CF}_2\text{CF}_3$ , and  $\text{CH}_2\text{CF}_3$ .
30. A pharmaceutical composition as claimed in claim 14 for treatment of a mood disorder selected from the group consisting of rheumatoid arthritis and osteoarthritis, pain, asthma, psoriasis and allergies.
31. A pharmaceutical composition as claimed in claim 14 for treatment of an inflammatory disorder selected from the group consisting of rheumatoid arthritis and osteoarthritis.
- Sub B4*
32. A pharmaceutical composition as claimed in claim 14 for treatment of depression, selected from the group consisting of major depression, single episode depression, recurrent depression, child abuse induced depression.
33. A pharmaceutical composition as claimed in claim 14 for treatment of neurodegenerative diseases selected from the group consisting of Alzheimer's disease, Parkinson's disease and Huntington's disease.
34. A pharmaceutical composition as claimed in claim 14 for treatment of chemical dependencies or addictions, selected from the group consisting of dependencies or addictions to alcohol, cocaine, heroin, benzodiazepines, or other drugs.
35. A pharmaceutical composition as claimed in claim 14 for treatment of cerebral ischemia.
- 24* *Sub B5*
36. A pharmaceutical composition as claimed in claim 14 for treatment of stress induced immune dysfunctions selected from the group consisting of including porcine stress syndrome, bovine shipping fever, equine paroxysmal fibrillation, confinement dysfunction in chicken, sheering stress in sheep, and human animal interaction stress in dogs.
37. A pharmaceutical composition as claimed in claim 14 for treatment of fibromyalgia.
38. A pharmaceutical composition as claimed in claim 14 for treatment of anorexia or bulimia nervosa.